“Atirmociclib, our potential first-in-class CDK4 inhibitor is enrolling a second line Phase III trial, and we expect to start a first line Phase III study by early 2025.”

In context

“C. We are equally encouraged by the updated Phase I data we presented the ESMO for this ADC, and we are planning rotation enabling trials in 2025. Our [indiscernible] pipeline is expanding. We are studying another novel ADC, [indiscernible] in 2 ongoing registration intended trials in unfilial cancer. And MEBROMETOSTAN, our novel EZH2 inhibitor is another example of the progress we are making throughout our pipeline. This has been starting as a new potential treatment for men who have metastatic castration-resistant prostate cancer, and we are enrolling currently patients into Phase III studies. Finally, to build on the foundation for our drugs, we are making progress with development of 2 candidates we believe can replace the current backbones of HER positive HER2 negative breast cancer. Atirmociclib, our potential first-in-class CDK4 inhibitor is enrolling a second line Phase III trial, and we expect to start a first line Phase III study by early 2025. And we expect the first Phase III data in the coming months for vepdegestrant, an Eastern receptor [indiscernible] that we are codeveloping right now with [indiscernible]. Our fourth generation PCB candidate now in Phase II adult and pediatrics, covers 25 serotypes, including improved immunogenicity for serotype 3, very important, which is one of the largest remaining contributors of disease. We are focused on building on our leadership in the industry by continuing to expand balance sheet with our fifth generation candidate, which is in preclinical development that covers over 30 serotype. In the last several months, we have advanced the potential new vaccine against Seba, which is considered and urgent public health threat that lacks any approved vaccines. Leveraging experience from our”